Skip to main content
Top
Published in: AIDS and Behavior 2/2007

01-11-2007 | Original Paper

Cost and Threshold Analysis of Housing as an HIV Prevention Intervention

Authors: David R. Holtgrave, Kate Briddell, Eugene Little, Arturo Valdivia Bendixen, Myrna Hooper, Daniel P. Kidder, Richard J. Wolitski, David Harre, Scott Royal, Angela Aidala

Published in: AIDS and Behavior | Special Issue 2/2007

Login to get access

Abstract

The Housing and Health study examines the effects of permanent supportive housing for homeless and unstably housed persons living with HIV. While promising as an HIV prevention intervention, providing housing may be more expensive to deliver than some other HIV prevention services. Economic evaluation is needed to determine if investment in permanent supportive housing would be cost-saving or cost-effective. Here we ask––what is the per client cost of delivering the intervention, and how many HIV transmissions have to be averted in order to exceed the threshold needed to claim cost-savings or cost-effectiveness to society? Standard methods of cost and threshold analysis were employed. Payor perspective costs range from $9,256 to $11,651 per client per year; societal perspective costs range from $10,048 to $14,032 per client per year. Considering that averting a new case of HIV saves an estimated $221,365 in treatment costs, the average cost-saving threshold across the three study cities is 0.0555. Expressed another way, if just one out of every 19 Housing & Health intervention clients avoided HIV transmission to an HIV seronegative partner the intervention would be cost-saving. The intervention would be cost-effective if it prevented just one HIV transmission for every 64 clients served.
Literature
go back to reference Aidala, A., Cross, J. E., Stall, R., Harre, D., & Sumartojo, E. (2005). Housing status and HIV risk behaviors: Implications for prevention and policy. AIDS & Behavior, 9, 251–265.CrossRef Aidala, A., Cross, J. E., Stall, R., Harre, D., & Sumartojo, E. (2005). Housing status and HIV risk behaviors: Implications for prevention and policy. AIDS & Behavior, 9, 251–265.CrossRef
go back to reference Gold, M. R., Siegel J. E., Russell L. B., Weinstein M. C. (Eds.) (1996). Cost-effectiveness in health and medicine. New York, NY: Oxford University Press. Gold, M. R., Siegel J. E., Russell L. B., Weinstein M. C. (Eds.) (1996). Cost-effectiveness in health and medicine. New York, NY: Oxford University Press.
go back to reference Gorsky, R. D. (1996). A method to measure the costs of counseling for HIV prevention. Public Health Reports, 111, 115–122.PubMed Gorsky, R. D. (1996). A method to measure the costs of counseling for HIV prevention. Public Health Reports, 111, 115–122.PubMed
go back to reference Holtgrave D. R. (Ed.) (1998). Handbook of economic evaluation of HIV prevention programs. New York, NY: Plenum Press. Holtgrave D. R. (Ed.) (1998). Handbook of economic evaluation of HIV prevention programs. New York, NY: Plenum Press.
go back to reference Holtgrave, D. R., & Pinkerton, S. D. (1997). Updates of cost of illness and quality of life estimate for use in economic evaluation of HIV prevention programs. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 16, 54–62.PubMed Holtgrave, D. R., & Pinkerton, S. D. (1997). Updates of cost of illness and quality of life estimate for use in economic evaluation of HIV prevention programs. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 16, 54–62.PubMed
go back to reference Hutchinson, A. B., Farnham, P. G., Dean, H. D., Edwueme, D. U., del Rio, C., Kamimoto, L., & Kellerman, S. E. (2006). The economic burden of HIV in the United States in the era of highly active antiretroviral therapy: Evidence of continuing racial and ethnic differences. Journal of Acquired Immune Deficiency Syndromes, 43, 451–457.PubMedCrossRef Hutchinson, A. B., Farnham, P. G., Dean, H. D., Edwueme, D. U., del Rio, C., Kamimoto, L., & Kellerman, S. E. (2006). The economic burden of HIV in the United States in the era of highly active antiretroviral therapy: Evidence of continuing racial and ethnic differences. Journal of Acquired Immune Deficiency Syndromes, 43, 451–457.PubMedCrossRef
go back to reference Pinkerton, S. D., Johnson-Masotti, A. P., Holtgrave, D. R., & Farnham, P. G. (2001). Using cost-effectiveness league tables to compare interventions to prevent sexual transmission of HIV. AIDS, 15, 917–928.PubMedCrossRef Pinkerton, S. D., Johnson-Masotti, A. P., Holtgrave, D. R., & Farnham, P. G. (2001). Using cost-effectiveness league tables to compare interventions to prevent sexual transmission of HIV. AIDS, 15, 917–928.PubMedCrossRef
go back to reference Prosser, L. A., Buxton Bridges, C., Uyeki, T. M., Hinrichsen, V. L., Meltzer, M. I., Nolinari, N-A. M., Schwartz, B., Thompson, W. W., Fukuda, K., & Lieu, T. A. (2006). Health benefits, risks, and cost-effectiveness of influenza vaccination of children. Emerging Infectious Diseases, 12, 1548–1558.PubMed Prosser, L. A., Buxton Bridges, C., Uyeki, T. M., Hinrichsen, V. L., Meltzer, M. I., Nolinari, N-A. M., Schwartz, B., Thompson, W. W., Fukuda, K., & Lieu, T. A. (2006). Health benefits, risks, and cost-effectiveness of influenza vaccination of children. Emerging Infectious Diseases, 12, 1548–1558.PubMed
go back to reference Schackman, B. R., Gebo, K. A., Walensky, R. P., Losina, E., Muccio, T., Sax, P. E., Weinstein, M. C., Seage, G. R. 3rd, Moore, R. D., & Freedberg, K. A. (2006). The lifetime cost of current human immunodeficiency virus care in the United States. Medical Care, 44, 990–997.PubMedCrossRef Schackman, B. R., Gebo, K. A., Walensky, R. P., Losina, E., Muccio, T., Sax, P. E., Weinstein, M. C., Seage, G. R. 3rd, Moore, R. D., & Freedberg, K. A. (2006). The lifetime cost of current human immunodeficiency virus care in the United States. Medical Care, 44, 990–997.PubMedCrossRef
go back to reference Trentacoste, N. D., Holtgrave, D. R., Collins, C., & Abdul-Quader, A. (2004). Disseminating effective behavioral interventions for HIV prevention: A cost analysis of a risk-reduction intervention for drug users. Journal of Public Health Management and Practice, 10, 130–139.PubMed Trentacoste, N. D., Holtgrave, D. R., Collins, C., & Abdul-Quader, A. (2004). Disseminating effective behavioral interventions for HIV prevention: A cost analysis of a risk-reduction intervention for drug users. Journal of Public Health Management and Practice, 10, 130–139.PubMed
go back to reference Varghese, B., Peterman, T. A., & Holtgrave, D. R. (1999). Cost-effectiveness of counseling and testing and partner notification: A decision analysis. AIDS, 13, 1745–1751.PubMedCrossRef Varghese, B., Peterman, T. A., & Holtgrave, D. R. (1999). Cost-effectiveness of counseling and testing and partner notification: A decision analysis. AIDS, 13, 1745–1751.PubMedCrossRef
Metadata
Title
Cost and Threshold Analysis of Housing as an HIV Prevention Intervention
Authors
David R. Holtgrave
Kate Briddell
Eugene Little
Arturo Valdivia Bendixen
Myrna Hooper
Daniel P. Kidder
Richard J. Wolitski
David Harre
Scott Royal
Angela Aidala
Publication date
01-11-2007
Publisher
Springer US
Published in
AIDS and Behavior / Issue Special Issue 2/2007
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-007-9274-z

Other articles of this Special Issue 2/2007

AIDS and Behavior 2/2007 Go to the issue

Original Paper

Why Housing?

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.